Press Releases

All Releases
Mar 03, 2014
AngioDynamics to Present at the Barclays Global Healthcare Conference
ALBANY, N.Y. , March 3, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
Jan 09, 2014
AngioDynamics Reports Fiscal 2014 Second Quarter Financial Results
Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization, of $0.14 per share Adjusted EBITDA of $12.7 million Operating cash flow of $8.2 million Company raises low end of revenue guidance to $349-$353 million for FY14; reiterates adjusted
Dec 12, 2013
AngioDynamics to Report Fiscal 2014 Second Quarter Financial Results
ALBANY, N.Y. , Dec. 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 second quarter financial results
Dec 11, 2013
AngioDynamics Appoints John Soto Chief Commercial Officer
ALBANY, N.Y. , Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of John Soto as Chief Commercial Officer, a
Nov 04, 2013
AngioDynamics to Present at Upcoming Investor Conferences
ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
Oct 10, 2013
AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company
Sep 24, 2013
AngioDynamics Announces Debt Refinancing
ALBANY, N.Y. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it amended its existing credit facilities and successfully
Sep 19, 2013
AngioDynamics to Report Fiscal 2014 First Quarter Financial Results
ALBANY, N.Y. , Sept. 19, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 first quarter financial results
Displaying 121 - 140 of 629